Pavmed created the test to fill the market inefficiency around Barrett’s esophagus. Patients with esophageal cancer are often unaware of underlying BE and because of this 80 percent of patients with EAC die within five years of diagnosis.
Pavmed believes the EsoGuard test can capture $2 billion of the U.S. domestic market if it has “very modest penetration.”
More articles on surgery centers:
Maine hospital expanding through $83.8M project, including ASC
5 ASC developments worth $10M+
$7M orthopedic ASC opens in Ohio
